ClinicalTrials.gg
RecruitingNCT07037758DeLLphi-311Updated Sep 25, 2026

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

A Phase 1 interventional study of Tarlatamab and AB248 in Extensive Stage Small Cell Lung Cancer, sponsored by Amgen. Recruiting at 19 sites in 3 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Sep 25, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
380
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Small Cell Lung Carcinoma by Amgen — 4 open to participants now, 12 under way, 5 of them phase 3. Small Cell Lung Carcinoma · Amgen.

Planned enrollment
6th of 17
380 · median 252
Started
2025
with 3 others
Phase 1
7 of 19
3 open now
Primary completion
2028-03
later than 5 of 11 live
Registered
17th of 19
by date

Among the 19 studies in Small Cell Lung Carcinoma by Amgen, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 in phase 1, reaches primary completion later than 5 of the 11 other live ones, and was the 17th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

4 of the 19 studies in Small Cell Lung Carcinoma by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Small Cell Lung Carcinoma by Amgen, or all of them as a file.
02

Study summary

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248.

The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.

03

Conditions studied

  • Extensive Stage Small Cell Lung Cancer

Keywords

  • ES-SCLC
  • Tarlatamab
  • AMG 757
  • AB248
  • Imdelltra
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has provided before initiation of any study-specific activities/procedures.
  2. Participants ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.
  3. Participants with or cytologically confirmed ES-SCLC that has progressed or recurred following at least 1 line of anti-cancer therapy for ES-SCLC.
  4. Participants must have at least 1 as defined by 1.1 within 21-day screening period, not previously irradiated.
  5. Participants must have adequate organ function (hematological, coagulation, cardiac, pulmonary, kidney, and liver).
  6. Participants must submit a fresh tumor at screening unless a new biopsy cannot be performed safely or is infeasible. Participants who cannot provide fresh tissue may provide archival tissue that was collected after last anticancer therapy.

Exclusion criteria

Exclusion Criteria:

  1. Symptomatic central nervous system (CNS) .
  2. Participants with may be eligible if criteria defined in the protocol are met.
  3. Prior therapy with any delta-like ligand 3 (DLL3)-directed therapy (including tarlatamab).
  4. Prior interleukin (IL)-2, IL-7 or IL-15 targeted therapy.
  5. Baseline (at rest) requirement of supplemental oxygen.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    Dose Exploration

    Multiple dose levels of AB248 will be explored in combination with tarlatamab administered via intravenous (IV) infusion.

    Drug: Tarlatamab · Drug: AB248

  • Experimental
    Dose Expansion

    The dose expansion part will test tarlatamab in combination with the MTCD/recommended dose for expansion of AB248 identified in the dose exploration part. An optional cohort may be opened based on emerging data to study tarlatamab in combination with AB248 at a lower dose than the MTCD/recommended dose for expansion or with an alternative dose regimen at a AB248 dose lower than or equal to MTCD/recommended dose for expansion.

    Drug: Tarlatamab · Drug: AB248

Interventions

  • Administered as an IV infusion.

    Also known as: AMG 757, Imdelltra

  • DrugAB248

    Administered either as an IV infusion followed by a flush or using a syringe pump without a flush.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Clinically significant changes in vital signs and clinical laboratory tests will be reported as adverse events.

    Time frame: Up to 2.5 years

  2. Dose Exploration: Number of Participants with Dose-limiting Toxicities (DLTs)

    Time frame: Up to 35 days

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) of Tarlatamab

    Time frame: Up to approximately 21 weeks

  2. Minimum Serum Concentration (Cmin) of Tarlatamab

    Time frame: Up to approximately 21 weeks

  3. Area Under the Concentration-time Curve (AUC) of Tarlatamab

    Time frame: Up to approximately 21 weeks

  4. Half-life (t1/2) of Tarlatamab

    Time frame: Up to approximately 21 weeks

  5. Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    Time frame: Up to 2.5 years

  6. Duration of Response (DOR) per RECIST 1.1

    Time frame: Up to 2.5 years

  7. Time to Response (TTR) per RECIST 1.1

    Time frame: Up to 2.5 years

  8. Disease Control (DC) per RECIST 1.1

    Time frame: Up to 2.5 years

  9. Progression-free Survival (PFS) per RECIST 1.1

    Time frame: Up to 2.5 years

  10. Time to Progression (TTP) per RECIST 1.1

    Time frame: Up to 2.5 years

  11. Time to Subsequent Therapy

    Time frame: Up to 2.5 years

  12. Overall Survival (OS)

    Time frame: Up to 2.5 years

  13. Number of Participants with Anti-AB248 Antibody Formation

    Time frame: Up to 2.5 years

07

Study locations

18 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Mar 2028, 30 months after the start.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's planned 30 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jun 25, 2025
StartActual
Sep 16, 2025
Primary completionEst.
Mar 18, 2028
CompletionEst.
Jan 18, 2031
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Banner MD Anderson Cancer Center is now Terminated
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Banner MD Anderson Cancer Center is now Terminated
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07037758
Lead sponsor
Amgen
Collaborators
Asher Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Sep 16, 2025
Primary completion
Mar 18, 2028 (estimated)
Completion
Jan 18, 2031 (estimated)
Last update
Sep 25, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etakafusp alfa

Start the discussion